Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck Read More

2024-03-25T08:36:04-04:00September 9th, 2019|Evidence, MammaPrint, Other, Validation|

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

2024-03-25T08:36:57-04:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More

2024-03-25T08:46:25-04:00August 2nd, 2019|Adjuvant, Evidence, MammaPrint, MINDACT, Other, Validation|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

2024-03-25T11:24:02-04:00June 1st, 2019|Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe|

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More

2024-03-25T08:57:37-04:00January 11th, 2018|Adjuvant, Evidence, MammaPrint, PROMIS|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:  Laura J. Esserman, MD, Read More

2024-06-28T12:13:13-04:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|
Go to Top